222
Participants
Start Date
March 9, 2017
Primary Completion Date
March 23, 2020
Study Completion Date
March 23, 2020
SOF/VEL for 6 weeks
Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
SOF/VEL for 12 weeks
Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
Auckland City Hospital, Auckland
Kirketon Road Centre, Sydney
St. Vincent's Hospital, Sydney
The Kirby Institute, University of New South Wales Australia, Sydney
The Alfred Hospital, Melbourne
Bern University Hospital, Bern
Royal Melbourne Hospital, Melbourne
Royal Adelaide Hospital, Adelaide
Fondazione Epatocentro Ticino, Lugano
University Hospital Zurich, Zurich
Praxis Dr Cordes, Berlin
Zentrum für Infektiologie Berlin-Prenzlauer Berg, Berlin
Johns Hopkins University, Baltimore
University Hospital of Bonn, Bonn
Infektio-Research GmbH, Frankfurt
Massachusetts General Hospital, Boston
St Paul's Hospital, Vancouver
Cool Aid Community Health Centre, Victoria
Toronto General Hospital, Toronto
Centre Hospitalier de l' Universite de Montreal, Montreal
Academic Medical Centre, University of Amsterdam, Amsterdam
Brighton & Sussex University Hospitals NHS Trust, Brighton
Pennine Acute Hospitals NHS Trust, Manchester
Royal Free Hospital, London
Chelsea & Westminster Hospital, London
Lead Sponsor
Kirby Institute
OTHER_GOV